Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study
This study was a single-centered, parallel-grouped, randomized clinical trial (RCT). We randomly assigned hyperuricemia participants with eGFR 20 –60 mL/min/1.73 m2 into benzbromarone and febuxostat treatment group. Drugs were adjusted by titration from small doses.ResultsSeventy-three eligible participants enrolled, 66 subjects (33 in each group) were included finally for analysis. When compared to baseline, serum uric acid (SUA) decreased significantly after treatment in both groups, but no differences were detected among all the follow-up points. After 12-month treatment, eGFR did not have significant change in both groups. In the benzbromarone group, kidney stones in one case increased in quantity. In the febuxostat group, kidney stones in one case became smaller in size and in two cases vanished completely. Both drugs did not increase myocardial enzymes significantly after the treatment. In addition, hemoglobin increased significantly in the two groups (p
Authors: Dayanand P, Sandhyavenu H, Dayanand S, Martinez J, Rangaswami J Abstract Vascular calcification is known to be a strong risk factor for cardiovascular adverse events and mortality. Atherosclerosis, diabetes, aging, abnormal bone mineral homeostasis and high uremic milieu such as chronic kidney disease are major factors that contribute to the progression of vascular calcification. Several mechanisms such as the osteoblastic transition of vascular smooth muscle cells in response to oxidative stress have shed light on the active nature of vascular calcification, which was once thought to be a passive process....
CONCLUSIONS: High age and posterior bleeding source seem to raise the necessity of inpatient therapy. In most cases tamponade is sufficient for treatment. Initial laboratory tests are of limited use to estimate risk of recurrence, but is necessary for patients taking coumarins to determine INR control. PMID: 29915939 [PubMed - as supplied by publisher]
Conclusions: These data suggest that in differentiated proximal tubules energetic hyperactivity is promoted concurrently with organ fibrogenesis.Cell Physiol Biochem 2018;47:1338 –1351
Conclusions: Sonidegib is a novel inhibitor of erythrocyte cell membrane scrambling following energy depletion, hyperosmotic shock and oxidative stress.Cell Physiol Biochem 2018;47:1352 –1364
Condition: Anemia in Pregnancy Intervention: Dietary Supplement: Vitamin C Sponsors: Fetal Medicine Foundation; Wright State University; Five Rivers Health Centers Not yet recruiting
Condition: CKD Stage 5 Interventions: Drug: EffCaMgCit; Other: CaAcS Sponsor: University of Texas Southwestern Medical Center Recruiting
Conditions: Anemia, Iron-Deficiency; Colorectal Cancer Intervention: Drug: iron isomaltoside(Monofer®) Sponsor: Prince of Wales Hospital, Shatin, Hong Kong Not yet recruiting
Condition: Anemia, Iron Deficiency Intervention: Sponsor: CAMC Health System Not yet recruiting
This report details the perioperative considerations used for successful CPB on a Waldenström's patient. Critical to this case was the use of plasmapheresis before surgery. Temperature management and acid/base status were carefully controlled. A successful coronary revascularization surgery was performed. Many of the Wadenstrom's disease complications expected on CPB failed to materialize. PMID: 29921992 [PubMed - in process]
The proclamation that “the greatest medicine of all is to teach people how not to need it” (Hippocrates. 460-370 BC, Greece) is the basic principle of primary disease prevention, which aims to prevent disease before it ever occurs. Preventing exposures to hazards that cause disease, such as altering unhealthy behavio rs, is one example of primary disease prevention. Secondary or tertiary disease prevention, however, refers to reducing the impact of a disease that has already occurred, or limiting the impact of an ongoing illness that has lasting effects, respectively.